- Home
- MAA vs BIIB Comparison
MAA vs BIIB Comparison
Compare MAA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAA
- BIIB
- Stock Information
- Founded
- MAA 1977
- BIIB 1978
- Country
- MAA United States
- BIIB United States
- Employees
- MAA N/A
- BIIB N/A
- Industry
- MAA Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- MAA Real Estate
- BIIB Health Care
- Exchange
- MAA Nasdaq
- BIIB Nasdaq
- Market Cap
- MAA 18.2B
- BIIB 18.8B
- IPO Year
- MAA 1994
- BIIB 1991
- Fundamental
- Price
- MAA $148.57
- BIIB $127.04
- Analyst Decision
- MAA Buy
- BIIB Buy
- Analyst Count
- MAA 19
- BIIB 27
- Target Price
- MAA $176.79
- BIIB $187.83
- AVG Volume (30 Days)
- MAA 953.9K
- BIIB 1.5M
- Earning Date
- MAA 07-30-2025
- BIIB 07-31-2025
- Dividend Yield
- MAA 4.08%
- BIIB N/A
- EPS Growth
- MAA 0.75
- BIIB 26.39
- EPS
- MAA 4.81
- BIIB 10.12
- Revenue
- MAA $2,196,688,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- MAA $2.42
- BIIB N/A
- Revenue Next Year
- MAA $4.06
- BIIB N/A
- P/E Ratio
- MAA $30.89
- BIIB $12.56
- Revenue Growth
- MAA 1.55
- BIIB 1.59
- 52 Week Low
- MAA $137.51
- BIIB $110.04
- 52 Week High
- MAA $173.38
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- MAA 35.31
- BIIB 46.07
- Support Level
- MAA $148.93
- BIIB $125.24
- Resistance Level
- MAA $151.41
- BIIB $136.84
- Average True Range (ATR)
- MAA 2.66
- BIIB 3.04
- MACD
- MAA -0.14
- BIIB -0.89
- Stochastic Oscillator
- MAA 9.99
- BIIB 15.52
About MAA Mid-America Apartment Communities Inc.
Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.